Kiran Mazumdar Shaw is an Indian businesswoman and the founder of Biocon, India's largest biotechnology company. She has over 40 years of experience in the biotechnology industry. Some key points: - Founded Biocon in 1978 with just Rs. 10,000 in capital. Within a year, Biocon became the first Indian company to export enzymes to the US and Europe. - Under her leadership, Biocon has become a billion dollar company and India's largest biotech firm. It develops biosimilar drugs and is a leading manufacturer of insulin. - She is considered a pioneer in the Indian biotech sector and has helped establish several other biotech firms. Through her philanthropic foundation,

1. Kiran Mazumdar
Shaw
Presented by:
Prerna Nambiar
Ramki Thivya Muthu
Muthu Tharun Svarna

2. Life…
Schooling at Bishop Cotton Girls School & Mount Carmel College at
Bangalore
Born on 23rd March, 1953 in Bangalore
B.Sc in Zoology from Bangalore University
Qualified as a master brewer from Ballarat Universtiy, Australia
CMD, Biocon Ltd., India’s biggest Biotechnology Company
In 2004, she became India’s Richest Woman

3. Personal Life…
John Shaw headed a leading textiles MNC, Madura Coats from 1991 to 1998
as CMD.
Kiran Mazumdar Shaw is married to John Shaw, a Scotsman and Indophile.
Currently, John Shaw is Vice-Chairman of Biocon, Ltd.
She has huge collections of paintings and other art works.
She has also written a coffee table book named “Ale & Arty”- the story of
Beer.

4. Philanthropic activities
In 2004, Kiran started the Biocon Foundation to conduct
health, education, sanitation, and environmental programs
to benefit of the economically weaker sections of society.
All the clinics maintained by Biocon organize regular general
health checks in remote villages by bringing in physicians
and doctors from network hospitals. Each year, the
Foundation touches more than 300,000 lives through its
holistic healthcare approach.
She helped establish a 1,400-bed cancer care center at the
Narayana Health City campus at Boommasandra in 2007.

5. Personal Recognition…
NATIONAL INSTITUTE OF MARKETING MANAGEMENT, INDIA
ROTARY CLUB, KARNATAKA
PADMASHRI, GOI
INTERNATIONAL WOMENS ASSOCIATION, CHENNAI
ERNST & YOUNG
HIGHEST CIVILIAN HONOURS
EXPRESS PHARMACEUTICAL LEADERSHIP SUMMIT AWARD
FORBES LIST
1982
1983
1989
1999
2002
2005
2009
2010

6. BIOCON
India’s Leading Biotech enterprise
•Established in 1978
•Focus on development of Bio-pharmaceuticals
•1stin Asia & 16th in world in terms of revenue and market capitalization
•Syngene, India’s first bio-tech custom research company in drug discovery
•First company to manufacture human insulin Using a Pichia expression system
•India’s first billion dollar bio-tech company
Biocon's key innovations include insulin analogue Glargine, BASALOG® and
India's first indigenously produced monoclonal antibody BioMAb-EGFR® , for
head & neck cancer. INSU Pen® is a next generation affordable insulin delivery
device introduced in India by Biocon.

7. Journey of Biocon Under her wings..
In 1978 itself, she started Biocon in he garage in Bangalore with a capital of
Rs. 10,000.
In 1978, she joined Biocon Biochemicals Limited, of Cork, Ireland as a
Trainee Manager.
Within a year, Biocon became the first Indian company to manufacture and
export enzymes to USA and Europe.
In 1990, she upgraded Biocon’s in-house research program, based on a
proprietary solid substrate fermentation technology.
The commercial success of this program led to a three-fold expansion by
1996 and Biocon entered the biopharmaceuticals and statins segments
In 1998, when Unilever agreed to sell its shareholding in Biocon to the
Indian promoters, Biocon became an independent entity.
Within a year, Biocon became the first Indian company to manufacture and
export enzymes to USA and Europe.
In 1990, she upgraded Biocon’s in-house research program, based on a
proprietary solid substrate fermentation technology.

8. By 2003 Biocon became the first company worldwide to develop human
insulin on a Pichia expression system.
In 2000, Biocon's proprietary bioreactor, christened PlafractorTM, based on
solid matrix fermentation received a U.S. patent.
In 2004, she decided to access the capital markets to develop Biocon’s
pipeline of research programs.
Biocon’s IPO was oversubscribed 32 times and its first day at the bourses
closed with a market value of $1.11 billion.
It made Biocon the 2nd only company to cross $1 billion mark on the first day
of listing.
She entered into more than 2,200 high-value R&D licensing and other deals
within the pharmaceuticals and bio-pharmaceutical space between 2005 &
2010

9. Biocon’s state of the art Human Insulin Facility

10. Business in BIOCON
Split Business Technique(SBT)
Divided business:
Syngene - company dealing in laboratory setups and
micro-biological reasearch
Clinigene – clinical research organisation
Biocon – biotechnology products
All these companies are owned by Kiran M. Shaw
which makes her the richest lady in India.

11. Departments of Biocon
Top Management
Middle level Management
HRM
FINANCE
MARKETTING
OPERATIONS
IT
QA & QC
PACKAGING
REGULATORY AFFAIRS

12. HRM in Biocon
† Biocon employees
approximately 3600
qualified personnel.
† 15% of Biocon are women
† The average age of
employees is 29 years.

13. Products Of Biocon
Anti-Diabetic Agents
Anti-Hypertensive Agents
Anti-Inflammatory Agents
Antioxidants
Cardiovascular Agens
Digestive Aid Enzymes
Haemostatic Agents
Hepatoprotective Agents
Immunosuppressants
Nutraceuticals

14. Financial Front
The paid up capital of Syngene as on March 31st, 2009
is Rs.28,750,000.
The paid up capital of Clinigene as on March 31st, 2009
is Rs.500,000.
The subscribed capital on 31st, 2008 of Axicorp is
7,950,000.
The paid up capital of BBPL as on March 31st 2009 is
Rs. 176,000,000.
The paid up capital of NeoBiocon as on March 31st
2009 is 45,250,000.
SHARE PRICE – 228.95 (BSE)

15. Biocon’s Achievement…
Med Ad News, in its 2007/08
listings has ranked Biocon 20th
amongst the leading
biotechnology companies in the
world.
Med Ad News, in its 2007/08
listings also ranked Biocon as
7th Largest Employer in the
world.
Biocon also recently received
the 2009 Bio Singapore Asia
Pacific Biotechnology Award for
Best Listed Company